Stockreport

FDA approves Novo Nordisk's Awiqli®, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes [Yahoo! Finance]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF Awiqli ® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per week The Awiqli ® approv [Read more]